Cadrenal Therapeutics, Inc. 8-K

What Happened

• On June 18, 2026, Cadrenal Therapeutics, Inc. filed a Current Report on Form 8‑K and issued a press release announcing plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration for tecarfarin.
• The RPDD request targets use of tecarfarin for pediatric patients with Kawasaki disease who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation.
• The company also disclosed a dual-track portfolio strategy: a Global Pharma Track centered on CAD-1005 (a first‑in‑class 12‑LOX inhibitor) and a Regional & Rare Disease Track focused on tecarfarin for Kawasaki disease.

Key Details

• Filing/announcement date: June 18, 2026 (Form 8‑K and press release).
• Target indication for RPDD: pediatric Kawasaki disease patients with CAAs requiring chronic oral anticoagulation.
• Pipeline highlights: CAD‑1005 (first‑in‑class 12‑LOX inhibitor) and tecarfarin (regional/rare disease focus).

Why It Matters

• The company is pursuing a formal pediatric regulatory pathway for tecarfarin, which clarifies its development focus and could affect clinical and regulatory planning.
• The portfolio update clarifies management’s strategic priorities—advancing CAD‑1005 globally while pursuing a rare pediatric/regional strategy for tecarfarin—which investors can use to assess near‑term milestones and resource allocation.